Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10610009 | 1.00 | ECE1 (0.49) | ECE1TGFBR1PDCD1LG2CD274ITGB2 | |
| SCHEMBL14199842 | 0.85 | ECE1 (0.50) | ECE1TGFBR1PDCD1LG2CD274ITGB2 | |
| SCHEMBL5144356 | 0.85 | ECE1 (0.45) | ECE1PDCD1LG2CD274ITGB2ICAM1 | |
| SCHEMBL16750044 | 0.85 | ECE1 (0.50) | ECE1TGFBR1PDCD1LG2CD274ITGB2 | |
| SCHEMBL5430130 | 0.85 | ECE1 (0.45) | ECE1PDCD1LG2CD274ITGB2ICAM1 | |
| SCHEMBL14179672 | 0.85 | ECE1 (0.50) | ECE1TGFBR1PDCD1LG2CD274ITGB2 | |
| SCHEMBL8601335 | 0.84 | ECE1 (0.47) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL3995863 | 0.83 | MME (0.44) | CA2ALDH1A1MMEFOLH1NAALAD2 | |
| SCHEMBL2916475 | 0.83 | MME (0.44) | CA2ALDH1A1MMEFOLH1NAALAD2 | |
| SCHEMBL23222804 | 0.82 | ECE1 (0.47) | ECE1TGFBR1PDCD1LG2CD274ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108152513-B | Overall molecular weight determination of protein-coupled reagent compounds | 西雅图基因公司 | 2020-07-24 | — | — | CN | claimed |
| US-20170281559-A1 | STEALTH, TARGETED NANOPARTICLES (STN) FOR ORAL DRUG DELIVERY | CHAUDHARY MANU (IN) | 2017-10-05 | — | — | US | claimed |
| CN-103858003-A | Overall molecular weight determination of protein-coupled reagent compounds | SEATTLE GENETICS INC | 2014-06-11 | — | — | CN | claimed |
| CN-102844021-A | Polymer/liposome nanocomposite composition for percutaneous absorption and preparation method thereof | AMOREPACIFIC CORP | 2012-12-26 | — | — | CN | claimed |
| EP-1322411-B1 | COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR CARRYING ACTIVE PRINCIPLES AND THEIR MODE OF PREPARATION | FLAMEL TECH SA (FR) | 2007-01-17 | — | — | EP | claimed |
| EP-1322411-A1 | COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR CARRYING ACTIVE PRINCIPLES AND THEIR MODE OF PREPARATION | FLAMEL TECHNOLOGIES (FR) | 2003-07-02 | — | — | EP | claimed |
| WO-2002028521-A1 | COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR CARRYING ACTIVE PRINCIPLES AND THEIR MODE OF PREPARATION | FLAMEL TECHNOLOGIES (FR) | 2002-04-11 | — | — | WO | claimed |
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12522590-B2 | Brefeldin a derivatives, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2026-01-13 | — | — | US | disclosed |
| CN-117929753-A | Detection and quantification of glycosylated peptides | 瑞泽恩制药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117858631-A | Nutritional composition | 森永乳业株式会社 | 2024-04-09 | — | — | CN | disclosed |
| CN-112513640-B | Detection and quantification of glycosylated peptides | 瑞泽恩制药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116745609-A | Method for identifying disordered disulfide bonds in biomolecules | 瑞泽恩制药公司 | 2023-09-12 | — | — | CN | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1322411-B1 | COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR CARRYING ACTIVE PRINCIPLES AND THEIR MODE OF PREPARATION | FLAMEL TECH SA (FR) | 2007-01-17 | — | — | EP | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| CN-1392877-A | Protein hydrolysate, method for producing same, and food and drink containing same | MORINAGA MILK INDUSTRY CO LTD (JP) | 2003-01-22 | — | — | CN | disclosed |
| CN-1342266-A | Method and kit for extracting prion protein | US AGRICULTURE (US) | 2002-03-27 | — | — | CN | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |
| CN-1038748-C | Method for preparing sulfonamide fibrinogen receptor antagonists | MERCK & CO INC (US) | 1998-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | BCL6, BCL6B, BCL3 | ECE1 4286/4885TGFBR1 4414/4885PDCD1LG2 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.